LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Colivicchi Furio, Fabbri Gianna, Oliva Fabrizio, Abrignani Maurizio Giuseppe, Arca Marcello, Averna Maurizio, Catapano Alberico Luigi, Ceseri Martina, Di Fusco Stefania Angela, Di Lenarda Andrea, Fattirolli Francesco, Gabrielli Domenico, Gonzini Lucio, Gulizia Michele Massimo, Riccio Carmine, Temporelli Pier Luigi, Aloia Antonio, Alonzo Alessandro, Aschieri Daniela, Barbato Emanuele, Bertoli Daniele, Calabrò Paolo, Calò Leonardo, Carugo Stefano, Crisci Vincenzo, La Rosa Giuseppe, Maffei Simone, Navazio Alessandro, Pavan Daniela, Scelza Nicola, Scicchitano Pietro, Themistoclakis Sakis, Maggioni Aldo Pietro, on the behalf of BRING-UP Prevention
Аннотация
METHODS: BRING-UP Prevention is an observational, prospective, multicentre study on patients with an atherothrombotic event enrolled in 2 phases: an educational intervention followed by two 3-months data collection, followed by 6 and 12-month follow-up, when the primary, secondary and exploratory endpoints will be evaluated. Clinical characteristics, treatments and target achievement for LDL cholesterol and other modifiable risk factors at baseline are reported in this manuscript.
RESULTS: From September 2023 to February 2024, 189 cardiology centers included 4790 patients, 2500 hospitalized, and 2290 managed as outpatients. Of the 4790 patients, 98 % had CAD, 6.1 % CVD, and 6.9 % PAD. Mean age was 67 ± 11 years, 20 % were females. Patients with LDL-C levels <55 mg/dL were 32.6 %. Patients at target for blood pressure were 39.2 %. Diabetic patients were 27.5 %, HbA1c <7 % was reported in 43.5 % of them. Statins prescription increased from 69 % at entry to 96 % at discharge/end of visit. In 74.5 % of patients, statins were prescribed in combination with ezetimibe. PCSK9-i or inclisiran were prescribed in a low rate of patients.
CONCLUSION: These data show that a low percentage of patients was at goal for LDL-C level and blood pressure. The 6-month follow-up visit will allow us to evaluate the changes in modifiable risk factors.